Plain-English translation of NCT07385001 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether ivonescimab, a new immunotherapy drug, works better when combined with two chemotherapy drugs (albumin-paclitaxel and cisplatin) before surgery for advanced esophageal cancer. The research is divided into two phases: the first phase tests the right dose and safety, and the second phase tests how well the combination actually works. This treatment is given before surgery to try to shrink the tumor and make surgery more successful.
Esophageal squamous cell carcinoma is a serious cancer that is difficult to treat. While chemotherapy has been used before surgery for many years, doctors believe adding this new immunotherapy medication might help the treatment work better and give patients a better chance of survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new medication ivonescimab by IV infusion every three weeks, combined with chemotherapy drugs. The treatment phase lasts about 9 weeks (three cycles of treatment), after which you will have surgery to remove the tumor. You will have regular blood tests, imaging scans, and clinic visits to monitor how you're responding and to check for any side effects before and after surgery.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China